CLAIMS

1. Use of a bromodomain and extra terminal (BET) inhibitor in the manufacture of a medicament for the treatment of cancer in combination with a protein phosphatase 2A (PP2A) activator..

2. Use of a protein phosphatase 2A (PP2A) activator in the manufacture of a medicament for the treatment of cancer in combination with a bromodomain and extra terminal (BET) inhibitor.

3. The use of claim 1 or claim 2, wherein the cancer is resistant to treatment by the BET inhibitor alone.

4. The use of any one of claims 1-3, wherein the BET inhibitor and the PP2A activator are synergistic in treating the cancer, compared to the BET inhibitor alone or the PP2A activator alone.

5. The use of any one of claims 1-4, wherein the BET inhibitor is a bromodomain-containing protein 2 (BRD2) inhibitor, bromodomain-containing protein 3 (BRD3) inhibitor, or bromodomain-containing protein 4 (BRD4) inhibitor.

6. The use of claim 5, wherein the BET inhibitor is a small molecule.

7. The use of claim 6, wherein the BET inhibitor is JQ1, JQ35, or a derivative thereof.

8. The use of any one of claims 1-7, wherein the PP2A activator is a small molecule.

9. The use of claim 7, wherein the PP2A activator is a phenothiazine compound or FTY720.

10. The use of claim 9, wherein the phenothiazine compound is selected from the group

consisting of chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine, trifluoperazine and pharmaceutically acceptable salts and esters thereof.

11. The use of any one of claims 1-10, wherein the BET inhibitor and the PP2A activator are to be administered concurrently or sequentially.

12. The use of any one of claims 1-11, further comprising a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MED1) inhibitor which are to be administered to the subject.